logo-loader
viewOragenics Inc

Oragenics making 'great progress' enrolling patients in oral mucositis clinical trial

Oragenics (NYSE:OGEN) CEO Alan Joslyn caught up with Proactive at the BIO Investor Forum in San Francisco. 

Joslyn says Oragenics is making 'great progress' enrolling patients in oral mucositis clinical trial. Oral mucositis is a painful side effect in patients who are receiving chemotherapy in head and neck cancers.

Quick facts: Oragenics Inc

Price: 0.7667 USD

NYSE:OGEN
Market: NYSE
Market Cap: $42.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

iCoreConnect cloud-based software is a real game changer in healthcare

iCoreConnect (OTCQB: ICCT) President and CEO Robert McDermott joined Steve Darling from Proactive to discuss the company that provides HIPAA-compliant software for the medical and dental industries. McDermott discusses a few of their services, their recent revenue growth and why listing on...

15 hours, 45 minutes ago

2 min read